Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms ABS 103(Amberstone Biosciences), ABS103(Amberstone Biosciences) |
Target |
Action stimulants, agonists |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), Tumor-associated antigen agonists(Tumor-associated antigen agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 15 May 2024 |